Moderna Stock Price, News & Analysis

Moderna, Inc. (Nasdaq: MRNA) has received a conditional marketing authorization from the European Commission for its COVID-19 vaccine, allowing widespread vaccination in the EU. This follows recommendations from the European Medicines Agency (EMA) and marks the fourth authorization for the vaccine globally, after the U.S., Canada, and Israel. The EU's confirmed order commitment has increased to 160 million doses. Initial deliveries are expected to commence next week. Moderna highlights its role in tackling the pandemic through its innovative mRNA technology.

Moderna (Nasdaq: MRNA) announced that Israel’s Ministry of Health has authorized the import of its COVID-19 Vaccine. This marks the vaccine's third regulatory approval, following the U.S. and Canada. Moderna has secured a contract to supply 6 million doses, with deliveries expected to start soon. The decision is based on comprehensive scientific evidence, including data from its Phase 3 clinical study. The vaccine is currently under review for additional authorizations in various countries, including the EU and the UK.

Moderna (Nasdaq: MRNA) has increased its global production estimate for the COVID-19 Vaccine from 500 million to 600 million doses for 2021. The company aims to scale production to potentially 1 billion doses, expecting 100 million doses available in the U.S. by Q1 2021 and a total of 200 million by the end of Q2 2021. So far, approximately 18 million doses have been supplied to the U.S. government. Moderna has partnerships for production and has secured contracts for 200 million doses with the U.S. and 40 million with Canada.

Moderna, Inc. (Nasdaq: MRNA) will present an update on its mRNA development pipeline at the 39th annual J.P. Morgan Healthcare Conference. CEO Stéphane Bancel's presentation is scheduled for January 11, 2021, at 4:30 p.m. ET, accessible via a live webcast on Moderna's investor website. The company continues to advance mRNA science for various diseases through strategic collaborations, including partnerships with AstraZeneca, Merck, and DARPA. Moderna has been recognized as a leading biopharmaceutical employer by Science for six consecutive years.

Moderna (MRNA) announced the publication of interim safety and primary efficacy results from its Phase 3 trial of the COVID-19 Vaccine (mRNA-1273) in the New England Journal of Medicine. The two-dose regimen demonstrated a vaccine efficacy of 94.1% against COVID-19, with 196 confirmed cases during the study. The trial enrolled over 30,000 participants and showed favorable tolerability and safety. The company is planning additional studies, including for adolescents and pregnant women, while continuing to follow participants for long-term safety data.

Moderna (Nasdaq: MRNA) has entered into a supply agreement with the Republic of Korea to provide 40 million doses of the Moderna COVID-19 Vaccine, aiming for deliveries to commence in May 2021. Currently, the vaccine is not approved for use in South Korea, necessitating regulatory approvals prior to distribution. CEO Stéphane Bancel emphasized the agreement as a step towards a lasting collaboration with Korea. Moderna's mRNA technology aims to transform patient care across various diseases, while the vaccine has received emergency use authorization in the U.S. for individuals 18 and older.

Moderna (MRNA) is in discussions with the South Korean government to supply 40 million COVID-19 vaccine doses, with distribution planned to start in Q2 2021. The vaccine has received emergency use authorization but is not fully approved by the FDA. Moderna focuses on mRNA therapeutics and vaccines across various diseases, supported by alliances with major pharmaceutical companies. However, the company acknowledges risks related to regulatory approval, manufacturing, and vaccine efficacy, which may impact its financial outlook.

Moderna (Nasdaq: MRNA) announced CEO Stéphane Bancel's virtual participation in the Goldman Sachs 13th Annual Healthcare CEOs Unscripted Conference on January 5, 2021, at 8:00 a.m. ET. A live webcast will be accessible in the Investors section on the Moderna website, with a replay available for 90 days post-event. Moderna is pioneering mRNA science to create transformative medicines, addressing various diseases through a robust pipeline of therapeutics and vaccines, in collaboration with strategic partners like AstraZeneca and Merck.

Moderna, Inc. (Nasdaq: MRNA) announced that Health Canada has authorized its COVID-19 vaccine for individuals 18 and older under an Interim Order. This decision reflects a comprehensive review, including data from the Phase 3 COVE study with 30,000 participants. The Canadian government has increased its confirmed order for the vaccine by 20 million doses, totaling 40 million doses. The vaccine, which utilizes mRNA technology, is designed to protect against COVID-19. Moderna emphasizes ongoing collaboration with regulatory bodies to ensure vaccine efficacy and safety.